A Phase 2 interventional study of 440 mg naproxen sodium with 1000 mg acetaminophen and 220 mg naproxen sodium with 650 mg acetaminophen in Pain, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-12-05.
Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 15th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 17 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 290 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
104 studies in Pain by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 99 finished, 32 (32%) have results posted.
Among the 104 studies in Pain by Johnson & Johnson, this one is the 33rd largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 2, and was the 99th registered.
Johnson & Johnson’s Pain studies by the year they started, since 1986.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 104 in Pain:
This tab as a report to print or save as PDF → With an account.
Study assessing efficacy and safety of concomitantly dosed naproxen sodium with acetaminophen, compared with naproxen sodium, hydrocodone/acetaminophen and Placebo in a postoperative dental pain.
This is a randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the analgesic efficacy and safety of concomitantly administered naproxen sodium 440 mg with acetaminophen 1000 mg and concomitantly administered naproxen sodium 220 mg with acetaminophen 650 mg, compared with a fixed combination of hydrocodone 10 mg/acetaminophen 650 mg, naproxen sodium 440 mg, and placebo over a twelve-hour period after surgical extraction of four third molars.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
Drug: 440 mg naproxen sodium with 1000 mg acetaminophen
220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
Drug: 220 mg naproxen sodium with 650 mg acetaminophen
10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
Drug: 10 mg hydrocodone + 650 mg acetaminophen
440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
Drug: 440 mg naproxen sodium
Single dose of four placebo tablets
Drug: Placebo tablet
Drug pages: Naproxen · Acetaminophen
440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
Also known as: Naproxen Sodium with Acetaminophen - High Dose
Drug pages: Naproxen · Acetaminophen
220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
Also known as: Naproxen Sodium with Acetaminophen - Low Dose
Drug pages: Hydrocodone · Acetaminophen
10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
Also known as: Commercial Hydrocodone + Acetaminophen Tablet
440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
Also known as: Naproxen sodium
Single dose of four placebo tablets
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6)
Time-weighted sum of the pain intensity difference (SPID) score was measured using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-6 hours was from -60 to 60. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment. Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 6 hours.
Time frame: Baseline (0 hour) up to 6 hours post-dose
Time-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)
Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (12 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 12 hours.
Time frame: Baseline (0 hour) up to 12 hours post-dose
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6)
Time-weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 60. Higher scores was indicative of more pain relief.
Time frame: Baseline (0 hour) up to 6 hours post-dose
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8)
TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 80. Higher scores was indicative of more pain relief.
Time frame: Baseline (0 hour) up to 8 hours post-dose
Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)
TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores was indicative of more pain relief.
Time frame: Baseline (0 hour) up to 12 hours post-dose
Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8)
Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-8 hours was from -80 to 80. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (8 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 8 hours.
Time frame: Baseline (0 hour) up to 8 hours post-dose
Pain Relief (PAR) Scores at Individual Timepoints
Participants answered a question at individual time points: "how much relief do you have from your starting pain?" on a 11-point PR-NRS. Scale ranged from 0=no relief to 10=complete relief. Higher score indicated improvement in pain.
Time frame: 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours
Pain Intensity Difference (PID) Scores at Individual Time Points
Pain Intensity was self-reported over 12 hours, using a pain rating of 0-10 on the PI-NRS, with score ranged from 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to baseline at each time point after study drug administration.
Time frame: 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.25 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, and 12 hours
Participant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation
Participants were asked to rate their overall impression of the study medication using the following scale: poor (0), fair (1), good (2), very good (3), and excellent (4) where higher score represented better outcome.
Time frame: Up to 12 hours
| Milestone | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Started | 35 | 69 | 61 | 63 | 62 |
| Completed | 33 | 65 | 58 | 62 | 61 |
| Not completed | 2 | 4 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 0 | 1 |
Time-weighted sum of the pain intensity difference (SPID) score was measured using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-6 hours was from -60 to 60. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment. Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 6 hours.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 6 Hours (SPID 0-6) | 2.36 ± 2.181 | 25.59 ± 1.562 | 30.28 ± 1.677 | 33.77 ± 1.633 | 23.60 ± 1.651 |
Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (12 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 12 hours.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12) | 5.80 ± 4.666 | 50.07 ± 3.341 | 55.47 ± 3.587 | 66.43 ± 3.494 | 39.94 ± 3.533 |
Time-weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 60. Higher scores was indicative of more pain relief.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 6 Hours (TOTPAR 0-6) | 7.96 ± 2.581 | 35.20 ± 1.848 | 40.94 ± 1.984 | 45.13 ± 1.933 | 32.88 ± 1.954 |
TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 80. Higher scores was indicative of more pain relief.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 8 Hours (TOTPAR 0-8) | 11.12 ± 3.554 | 47.19 ± 2.545 | 54.37 ± 2.732 | 60.78 ± 2.662 | 41.61 ± 2.691 |
TOTPAR was measured using a PR-NRS ranging from 0-10 (0 = no relief, 10 = complete relief). Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each postdose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores was indicative of more pain relief.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12) | 18.20 ± 5.595 | 69.96 ± 4.006 | 76.80 ± 4.301 | 90.22 ± 4.190 | 57.03 ± 4.237 |
Time-weighted sum of the pain intensity difference score was measured using a PI-NRS ranging from 0-10 (0 = no pain, 10 = very severe pain). The possible range of SPID for 0-8 hours was from -80 to 80. A higher value of SPID indicated greater pain relief. PID was the difference between baseline pain intensity and pain intensity at assessment (8 hours). Time-weighted sum of the pain intensity difference scores were derived by first multiplying each PID score by the time from the previous time point and adding these time-weighted PID scores together over the intervals from 0 to 8 hours.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Time-Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 8 Hours (SPID 0-8) | 3.24 ± 2.981 | 34.11 ± 2.134 | 39.98 ± 2.291 | 45.27 ± 2.232 | 29.58 ± 2.257 |
Participants answered a question at individual time points: "how much relief do you have from your starting pain?" on a 11-point PR-NRS. Scale ranged from 0=no relief to 10=complete relief. Higher score indicated improvement in pain.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| 0.25 hours | 0.45 ± 0.26 | 0.80 ± 0.18 | 1.36 ± 0.20 | 1.07 ± 0.19 | 1.04 ± 0.20 |
| 0.5 Hours | 0.51 ± 0.44 | 2.27 ± 0.31 | 3.46 ± 0.33 | 4.03 ± 0.33 | 3.23 ± 0.36 |
| 0.75 Hours | 0.77 ± 0.48 | 4.11 ± 0.35 | 5.10 ± 0.37 | 5.71 ± 0.36 | 5.08 ± 0.36 |
| 1 Hours | 1.06 ± 0.49 | 5.29 ± 0.35 | 5.91 ± 0.38 | 6.60 ± 0.37 | 6.03 ± 0.37 |
| 1.25 Hours | 1.13 ± 0.49 | 5.99 ± 0.35 | 6.46 ± 0.38 | 7.17 ± 0.37 | 6.40 ± 0.37 |
| 1.5 Hours | 1.18 ± 0.48 | 6.36 ± 0.34 | 6.89 ± 0.37 | 7.65 ± 0.36 | 6.44 ± 0.36 |
| 2 Hours | 1.08 ± 0.48 | 6.62 ± 0.34 | 7.37 ± 0.37 | 7.97 ± 0.36 | 6.38 ± 0.36 |
| 3 Hours | 1.37 ± 0.49 | 6.52 ± 0.35 | 7.61 ± 0.38 | 8.24 ± 0.37 | 6.26 ± 0.37 |
| 4 Hours | 1.66 ± 0.51 | 1.46 ± 0.36 | 7.68 ± 0.39 | 8.46 ± 0.38 | 5.96 ± 0.38 |
| 5 Hours | 1.59 ± 0.52 | 6.45 ± 0.37 | 7.43 ± 0.40 | 8.23 ± 0.39 | 5.54 ± 0.40 |
| 6 Hours | 1.53 ± 0.53 | 6.26 ± 0.38 | 7.23 ± 0.41 | 8.15 ± 0.40 | 4.88 ± 0.40 |
| 7 Hours | 1.51 ± 0.55 | 6.05 ± 0.39 | 6.80 ± 0.42 | 7.94 ± 0.41 | 4.50 ± 0.41 |
| 8 Hours | 1.65 ± 0.54 | 5.95 ± 0.39 | 6.63 ± 0.42 | 7.71 ± 0.41 | 4.23 ± 0.41 |
| 9 Hours | 1.61 ± 0.56 | 5.73 ± 0.40 | 6.27 ± 0.43 | 7.44 ± 0.42 | 3.88 ± 0.43 |
| 10 Hours | 1.73 ± 0.58 | 5.71 ± 0.42 | 5.66 ± 0.45 | 7.49 ± 0.44 | 3.66 ± 0.44 |
| 11 Hours | 1.86 ± 0.60 | 5.71 ± 0.43 | 5.33 ± 0.46 | 7.26 ± 0.45 | 3.91 ± 0.46 |
| 12 Hours | 1.89 ± 0.61 | 5.62 ± 0.44 | 5.18 ± 0.47 | 7.25 ± 0.46 | 3.98 ± 0.46 |
Pain Intensity was self-reported over 12 hours, using a pain rating of 0-10 on the PI-NRS, with score ranged from 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to baseline at each time point after study drug administration.
| Units on a scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| 0.25 hours | 0.25 ± 0.21 | 0.58 ± 0.15 | 1.01 ± 0.16 | 0.85 ± 0.15 | 00.79 ± 0.16 |
| 0.5 Hours | 0.07 ± 0.33 | 1.82 ± 0.24 | 2.61 ± 0.25 | 3.06 ± 0.25 | 2.36 ± 0.25 |
| 0.75 Hours | 0.24 ± 0.38 | 3.15 ± 0.27 | 3.82 ± 0.29 | 4.31 ± 0.29 | 3.77 ± 0.29 |
| 1 Hours | 0.45 ± 0.39 | 3.97 ± 0.28 | 4.41 ± 0.30 | 4.95 ± 0.29 | 4.48 ± 0.30 |
| 1.25 Hours | 0.34 ± 0.40 | 4.50 ± 0.28 | 4.87 ± 0.30 | 5.42 ± 0.30 | 4.71 ± 0.30 |
| 1.5 Hours | 0.31 ± 0.39 | 4.72 ± 0.28 | 5.18 ± 0.30 | 5.76 ± 0.29 | 4.74 ± 0.30 |
| 2 Hours | 0.22 ± 0.40 | 4.87 ± 0.28 | 5.49 ± 0.31 | 6.01 ± 0.30 | 4.67 ± 0.30 |
| 3 Hours | 0.34 ± 0.41 | 4.75 ± 0.30 | 5.62 ± 0.32 | 6.17 ± 0.31 | 4.51 ± 0.31 |
| 4 Hours | 0.53 ± 0.43 | 4.63 ± 0.31 | 5.64 ± 0.33 | 6.31 ± 0.32 | 4.26 ± 0.33 |
| 5 Hours | 0.50 ± 0.44 | 4.59 ± 0.32 | 5.51 ± 0.34 | 6.13 ± 0.33 | 3.89 ± 0.34 |
| 6 Hours | 0.47 ± 0.44 | 4.50 ± 0.32 | 5.28 ± 0.34 | 6.06 ± 0.33 | 3.39 ± 0.34 |
| 7 Hours | 0.40 ± 0.45 | 4.36 ± 0.32 | 4.96 ± 0.34 | 5.82 ± 0.34 | 3.08 ± 0.34 |
| 8 Hours | 0.48 ± 0.45 | 4.17 ± 0.32 | 4.74 ± 0.34 | 5.68 ± 0.34 | 2.90 ± 0.34 |
| 9 Hours | 0.53 ± 0.46 | 4.04 ± 0.33 | 4.46 ± 0.35 | 5.41 ± 0.34 | 2.56 ± 0.35 |
| 10 Hours | 0.64 ± 0.40 | 4.01 ± 0.35 | 3.87 ± 0.37 | 5.43 ± 0.36 | 2.42 ± 0.37 |
| 11 Hours | 0.69 ± 0.50 | 3.99 ± 0.35 | 3.63 ± 0.38 | 5.16 ± 0.37 | 2.71 ± 0.37 |
| 12 Hours | 0.71 ± 0.50 | 3.91 ± 0.36 | 3.53 ± 0.38 | 5.16 ± 0.37 | 2.66 ± 0.38 |
Participants were asked to rate their overall impression of the study medication using the following scale: poor (0), fair (1), good (2), very good (3), and excellent (4) where higher score represented better outcome.
| Units on a Scale | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| Participant's Global Evaluation of Study Medication OR Overall Impression of Study Medication According to Participant's Global Evaluation | 0.8 ± 0.18 | 2.7 ± 0.13 | 2.9 ± 0.14 | 3.3 ± 0.13 | 2.7 ± 0.14 |
Collected over Up to Day 10. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Placebo | 0/35 (0%) | 0/35 (0%) | 14/35 (40%) |
| Arm 2: Naproxen Sodium 440 mg | 0/69 (0%) | 0/69 (0%) | 5/69 (7.2%) |
| Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | 0/61 (0%) | 0/61 (0%) | 8/61 (13.1%) |
| Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | 0/63 (0%) | 0/63 (0%) | 9/63 (14.3%) |
| Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg | 0/62 (0%) | 0/62 (0%) | 22/62 (35.5%) |
| Event | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 9/35 | 2/69 | 2/61 | 3/63 | 20/62 |
| VomitingGastrointestinal disorders | 7/35 | 2/69 | 4/61 | 6/63 | 9/62 |
| HeadacheNervous system disorders | 4/35 | 0/69 | 0/61 | 0/63 | 1/62 |
| Alveolar osteitisInfections and infestations | 0/35 | 1/69 | 3/61 | 1/63 | 0/62 |
| DizzinessNervous system disorders | 0/35 | 2/69 | 1/61 | 1/63 | 3/62 |
| Upper respiratory tract infectionInfections and infestations | 1/35 | 0/69 | 2/61 | 1/63 | 0/62 |
| DiarrhoeaGastrointestinal disorders | 1/35 | 0/69 | 0/61 | 0/63 | 0/62 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/35 | 0/69 | 0/61 | 0/63 | 0/62 |
| Postoperative wound infectionInfections and infestations | 0/35 | 0/69 | 0/61 | 1/63 | 1/62 |
| InfluenzaInfections and infestations | 0/35 | 1/69 | 0/61 | 0/63 | 0/62 |
| Age, Continuous(years) | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 18.4 ± 1.50 | 19.0 ± 2.39 | 18.2 ± 1.33 | 19.0 ± 2.23 | 18.3 ± 1.70 | 18.6 ± 1.95 |
| Sex: Female, Male(Participants) | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|---|
| Female | 19 | 36 | 33 | 35 | 32 | 155 |
| Male | 16 | 33 | 28 | 28 | 30 | 135 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 5 | 6 | 6 | 34 |
| Not Hispanic or Latino | 27 | 60 | 56 | 57 | 56 | 256 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1: Placebo | Arm 2: Naproxen Sodium 440 mg | Arm 3: Naproxen Sodium 220 mg + Acetaminophen 650 mg | Arm 4: Naproxen Sodium 440 mg + Acetaminophen 1000 mg | Arm 5: Hydrocodone 10 mg + Acetaminophen 650 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 1 | 1 | 4 |
| Asian | 0 | 3 | 2 | 4 | 1 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 | 2 | 0 | 6 |
| Black or African American | 1 | 1 | 0 | 0 | 0 | 2 |
| White | 32 | 61 | 57 | 54 | 57 | 261 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Data sharing details ↗ · yoda.yale.edu
Ran from May 2019 to primary completion in Nov 2019, 5 months.
Results were first posted in Dec 2022, 3 years after primary completion. A results delay was requested in Nov 2020.
Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naproxen · Acetaminophen
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division →